Detalles de la búsqueda
1.
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
Rheumatology (Oxford)
; 61(7): 2856-2866, 2022 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34730795
2.
Peptidase inhibitor 16 is a membrane-tethered regulator of chemerin processing in the myocardium.
J Mol Cell Cardiol
; 99: 57-64, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27539859
3.
MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.
Circulation
; 127(21): 2097-106, 2013 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23625957
4.
A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes.
J Mol Cell Cardiol
; 52(1): 13-20, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21801730
5.
Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
Trials
; 22(1): 543, 2021 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34404463
6.
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
BMJ Open
; 10(9): e039059, 2020 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32998926
7.
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy.
Nat Commun
; 3: 1078, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23011132
Resultados
1 -
7
de 7
1
Próxima >
>>